Samsung Biologics America, a subsidiary of Samsing Biologics, a CDMO, has entered into a definitive agreement to acquire 100% of Human Genome Sciences from GSK for $280 million. This strategic move secures Samsung Biologics’ first U.S.-based manufacturing site. Located in Rockville, Maryland, the facility encompasses two cGMP manufacturing plants with a combined 60,000 liters of drug substance capacity, supporting both clinical and commercial production from small to large scale. Existi...